Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-Transduced T-cells and Pembrolizumab in Metastatic Anal Cancer
NCT04536922Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Jan 2021
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TCR-transduced peripheral blood lymphocytes in squamous cell carcinoma of the anus, sponsored by National Cancer Institute. Planned start Jan 2021; status: withdrawn.
02
Drugs
TCR-transduced peripheral blood lymphocytes
03
Conditions
squamous cell carcinoma of the anus
Beyond the preview
Go deeper on NCT04536922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536922.